Jothydev Kesavadev
MD, FRCP(London), FACE, FRCP(Glasgow),
FRCP(Edinburgh), FACP, FRSSDI

Jothydev’s Diabetes & Research Center
JDC Junction, Mudavanmugal,
Trivandrum, Kerala, India 695032
tel +91 471 2356200
fax +91 471 2356666
cell +91 984 6040055
www.jothydev.net, jothydev@gmail.com

Research Diabetologist based in Kerala, South India.

    • Several National and International presentations and publications to his credit
    • Lectured at Scientific forums in more than 25 countries
    • First speaker from Kerala at American Diabetes Association (ADA)
    • First invited speaker from Kerala at International Diabetes Federation (IDF) and Advanced Technologies & Treatments for Diabetes (ATTD, Europe)
    • Delivered orations at KMC Manipal (2015), UPDA (2015), APICON (2016), and Diacon (2018), and lectured at the annual conferences of RSSDI, DiabetesIndia etc.
    • 10 years of experience as a medical teacher both for undergraduates and postgraduates
    • Much sought after national faculty
    • Introduced the telemedicine concept of patient follow up via Diabetes Tele Management System (DTMS®)
    • Introduced the multi-disciplinary professional team approach in Kerala
    • Internationally known expert in the field of Insulin pumps, Continuous Glucose Monitoring and Telemedicine
    • Editor of ‘Diabetes Gems’ a free internet-based scientific newsletter with more than 20,000 readers since 2008.
    • Organizer of 650 Diabscreen Kerala free diabetes awareness, detection and treatment medical camps across Kerala (a project of P. Kesavadev Trust)
    • Advocate of diabetes education through visual and print media including television and YouTube
    • Organizer of National and International conferences
    • Reviewer of more than a dozen scientific journals including Diabetes Care, Diabetes Technology & Therapeutics, Diabetes Science & Technology and Indian Journal of Endocrinology & Metabolism
    • His Centre in Trivandrum is an IDF recognized Centre of Excellence in Diabetes Care and Diabetes Education
    • His Centre in Trivandrum is accredited for running RSSDI Advanced Certificate Course in Diabetology for doctors
    • His Centre in Trivandrum is accredited as Centre of Excellence by Medtronic and Roche
    • The Institutional Ethics Committee of his Centre is accredited by NABH

Present Positions:

  • Chairman and Managing Director: Jothydev's Diabetes Research Center, Trivandrum
  • Chairman: Jothydev’s Diabetes Research Center, Cochin
  • Chairman: Jothydev’s Diabetes Research Center, Attingal
  • Chairman and Managing Trustee: Diabscreen Kerala, P. Kesavadev Trust
  • Managing Director: Living Longer Life Care Private Limited
  • Editor in Chief, International Journal of Diabetes and Technology
  • Executive Committee Member, South Zone, RSSDI
  • Vice Chairman, RSSDI Kerala Chapter
  • Chairman IMA, AMS Nemom
  • National President, Diabetes Technology Trust of India
  • Vice President, AIAARO Kerala Chapter
  • Associate Editor, Journal of Diabetology
  • Organizing Secretary, Jothydev’s Professional Education Forum Annual Convention

Previously:

  • Asst.Professor of Medicine: Government Medical College, Trivandrum- 2001-2002
  • Lecturer in Internal Medicine: Government Medical College, Trivandrum- 1994-2001

Education:

  • MBBS, Medical College, Trivandrum, Kerala, India: Dec 1989 (Undergraduate Course)
  • MD, Medical College, Trivandrum, Kerala, India: Oct 1996 (Postgraduate in Internal Medicine)
  • Endocrinology Research Fellow at Mayo Clinic, MN, USA: 2002- 2003
  • Fellow of the Royal College of Physicians (FRCP), Glasgow: 2014
  • Fellow of the American College of Physicians (FACP): 2015
  • Fellow of the Royal College of Physicians (FRCP), London:2016
  • Fellow of the Research Society for the Study of Diabetes in India (FRSSDI), India: 2017
  • Fellow of the American College of Endocrinology (FACE), USA: 2017
  • Fellow of the Royal College of Physicians (FRCP), Edinburgh: 2018

Teaching Experience:

  • Served as Asst.Professor of Medicine: Government Medical College, Trivandrum: 2001-2002
  • Served as Lecturer in Internal Medicine: Government Medical College, Trivandrum: 1994-2001
  • Teaching Faculty for the RSSDI Fellowship Course in Diabetology: 2014-present
  • Faculty for the Fellowship course in diabetes at Jothydev’s Diabetes Research Centre: 2014-present
  • Faculty for RSSDI Advanced Certificate Course in Diabetology for doctors
  • Faculty for the MSc.Cert. course in Endocrinology/Diabetes courses, South Wales University, UK: 2016 October (continuing)

Major areas of Research:

  • Diabetes Education, CGM, Insulin Pumps, Telemedicine

Memberships in Professional Associations:

  • American Association of Clinical Endocrinologists (AACE)
  • American Diabetes Association (ADA)
  • American Geriatrics Society (AGS)
  • European Association for the Study of Diabetes (EASD)
  • Research Society for the Study of Diabetes in India (RSSDI)
  • Association of Physicians India (API)
  • Indian Medical Association (IMA)
  • Geriatric Society of India
  • Indian Medical Association (AMS)
  • Diabscreen Kerala, doctor’s forum

Honors

  • 2023 Technology Innovation Award, International Symposium on Diabetes
  • 2022 Times of India, Excellence in Diabetes Care
  • 2022 American College of Physicians (ACP) Excellence Award, ACP India
  • 2022 Icon of the Year Award for Medical Innovation, 24 News Chanel
  • 2022 Diabetes Technology Award, Global Diabetes Forum
  • 2021 Diabetes Technology Man of Millennium, Asia Diabetes Forum
  • 2021 Best Researcher Award by International Academic Awards 2021, Science Father
  • 2021 Late Prof. B N Srivastava & Late (Mrs.) Sarandulari Srivastava Award, National RSSDI
  • 2020 The Golden Aim Award for Excellence and Leadership in Health
  • 2020 Outstanding Scientist Award at 9th International Scientist Awards on Engineering Science and Medicine
  • 2020 Award for Excellence in Diabetes Care from Lions Club International
  • 2019 World Medical Council Award for Excellence in Diabetes Care
  • 2019 Vayalar-Kesavadev Award by Vyloppilli Samskriti Bhavan
  • 2018 Best Doctor Award in Diabetes by Mangalam Publications
  • 2018 Distinguished Alumnus Award by Trivandrum Medical College Alumni Association
  • 2018 SNMS award by Sreenarayana Mandira Samithi, Mumbai
  • 2015 Jeevan Raksha Award by Anti Narcotic Action Centre of India
  • 2015 Sahridayavedi Award
  • 2014 Most Promising Healthcare Centre in diabetes education and treatment Award
  • 2014 Mahatma Gandhi Cultural Award
  • 2013 Incredible Medical Expert of the Decade Award
  • 2013 Award by Geriatric Society of India
  • 2011 International Kohinoor Award at Indo- Thai friendship and Economic Meet at Bangkok, Thailand.
  • 2008 Rajiv Gandhi Shiromani Award
  • 2007 Young achiever for 2007 by Humanity in Unity USA

Orations

  • 2021 Dr.Rema Mohan Gold Medal Oration at Dr. Mohan’s International Diabetes Update 2021 on ‘My journey with diabetes technologies since two decades’.
  • 2018 Diacon Gold Medal Oration at the 4th Annual Conference of Diacare (DIACON) on ‘Practice Changing User Friendly Diabetes Technologies - New for 2018 and beyond’.
  • 2016 Sanofi Aventis Diabetes Oration at the 71st Annual Conference of Physicians of India (APICON) on ‘Evolution of path-breaking technologies in diabetes’.
  • 2015 Uttarkhand Convocation Oration at the 14th Annual Convention, Uttar Pradesh Diabetes Association (UPDA), Nainital, on ‘Technological Innovations in Clinical Diabetology: Will it Redefine the Treatment Paradigm?’.
  • 2015 Gold Medal Oration at Kasturba Medical College, Manipal on ‘Newer Insulins and GLP-1 RAs: How to position in Clinical Practice?’.

Selected Original Research Publications:

  1. Fixed-dose combination of Canagliflozin and Metformin as an adjunct to diet and exercise in Indian adults with Type 2 diabetes mellitus: Results from a multicentric, open-label, single-arm, phase IV study. Magdum, M., Unnikrishnan, A. G., Farishta, F., Balamurugan, R., Murthy, S., Desai, P., Singh, K. P., Barauh, M., Rastogi, A., Kesavadev, J., Lakhani, P., Panchal, S., Korde, T., Acharya, R., & Dixit, J. J Assoc Physicians India. April 2024;72(4):13–20.
  2. Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System. Kesavadev J, Basanth A, Krishnan G, Shankar A, Sanal G, Jothydev S. Diabetes Therapy. 2023 Jun 6:1-2.
  3. Reducing the Cost of Diabetes Care with Telemedicine, Smartphone, and Home Monitoring. Kesavadev J, Mohan V. J Indian Inst Sci. 2023 Apr 2023.
  4. Intermittent Use of Continuous Glucose Monitoring: A New Paradigm in Treatment of Type 2 Diabetes. Saboo B, Unnikrishnan R, Kesavadev J, Tiwaskar M, Czupryniak L, Chawla M, Choudhary P, Battelino T, Agarwal S, Danne T, Mohan V. J Assoc Physicians India 2023;71(6):51–56.
  5. Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades. Saboo B, Chandalia H, Ghosh S, Kesavadev J, Kochar I, Prasannakumar KM, Sarda A, Bantwal G, Mehrotra RN, Rai M. Current Diabetes Reviews. 2023 Mar 10.
  6. Human Digital Twin for Personalized Elderly Type 2 Diabetes Management. Thamotharan P, Srinivasan S, Kesavadev J, Krishnan G, Mohan V, Seshadhri S, Bekiroglu K, Toffanin C. Journal of Clinical Medicine. 2023 Mar 7;12(6):2094.
  7. Comparing the benefits of applying a vacuum-assisted lancing device in reducing lancing pain, improving self-monitoring frequency, and reducing HbA1c in people with diabetes. Kesavadev J, Chandran GB, Basanth A, Krishnan G, Shankar A, Jothydev S. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2023 Mar 2:102731.
  8. Expert Consensus Recommendations on Time in Range for Monitoring Glucose Levels in People with Diabetes: An Indian Perspective. Mohan V, Joshi S, Mithal A, Kesavadev J, Unnikrishnan AG, Saboo B, Kumar P, Chawla M, Bhograj A, Kovil R. Diabetes Ther. 2023 Jan 27. doi: 10.1007/s13300-022-01355-4. PMID: 36705888.
  9. Addendum 1: Forum for Injection Technique and Therapy Expert Recommendations, India. Kalra S, Unnikrishnan AG, Prasanna Kumar KM, Sahay R, Chandalia HB, Saboo B, Annamalai S, Kesavadev J, Shukla R, Wangnoo SK, Baruah MP. Diabetes Therapy. 2022 Nov 15:1-7
  10. Health care delivery model in India with relevance to diabetes care. Das AK, Saboo B, Maheswari A, Banerjee S, Jayakumar C, Mohan AR, Potty VS, Kesavadev J. Heliyon. 2022 Oct 4:e10904.
  11. Insulin Degludec/Insulin Aspart (IDegAsp) safely improves HbA1c: a long‐term real‐world cohort study (IDEA). Kesavadev J, Saboo B, Kovil R, Joshi S, Shankar A, Ashik A, Ashok AD, Basanth A, Krishnan G. Diabetes, Obesity and Metabolism. 2022 Aug 20.
  12. Scientific advisory on nocturnal hypoglycemia in insulin-treated patients with diabetes: Recommendations from Indian experts. Chawla M, Chawla P, Saboo B, Chawla R, Gangopadhyay KK, Kalra S, Aravind S, Sinha BC, Shah T, Kesavadev J, Rajput R. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2022 Aug 23:102587.
  13. One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study). Kesavadev J, Murthy LS, Chaudhury T, Yalamanchi SR, Giri J, Gupta S, Phatak S, Modi KD, Chatterjee S, Manjunath A, Revanna M. Metabolism Open. 2022 Apr 18:100184.
  14. Empowering Patients with Type 1 Diabetes Through a Multidisciplinary Team-assisted, Technology-Enabled Education Program. Sanal G, Shijin S, Krishna V, Kesavadev J, Basanth A, Krishnan G, Shankar A. Curr Diabetes Rev. 2022 May 20. doi: 10.2174/1573399818666220520115420.
  15. Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment). Kesavadev J, Gowda A, Kumar H, Yalamanchi SR, Lodha S, Singh KP, Basu D, Asirvatham A, Shah N, Pathan MK, Revanna M. Medical Sciences. 2021 Dec 21;10(1):1.
  16. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs. Joshi S.R., Rajput R., Chowdhury S., Singh A.K., Bantwal G., Das A.K., Unnikrishnan A.G., Saboo B.D., Kesavadev J., Ghosal S. and Mohan V. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 16(6), June 2022, p.102508.
  17. Type 2 Diabetes in Women-Different and Difficult. Kesavadev J, Abraham G, Chandni R, Chawla P, Nambiar A, Deshpande N, Joshi S, Jothydev S, Krishnan G, Das A K. Current diabetes reviews. 7 Dec 2021.
  18. Time-in-range and frequency of continuous glucose monitoring: Recommendations for South Asia. Kesavadev J, Misra A, Saboo B, Agarwal S, Sosale A, Joshi S R, Hussain A, Somasundaram N, Basit A, Choudhary P, Soegondol S. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Nov 2021, 102345.
  19. Screening for Diabetes in India Should be Initiated at 25 Years Age. Misra A, Ramachandran A, Saboo B, Kesavadev J, Sosale A, Joshi S, Kumar Das A. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Oct 2021:102321.
  20. COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. Gupta R, Kesavadev J, Krishnan G, Agarwal S, Saboo B, Shah M, Mittal A, Durani S, Luthra A, Singhal A, Rasheed M. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Oct 2021:102322.
  21. Prescribing Patterns and Response to Antihyperglycemic Agents Among Novel Clusters of Type 2 Diabetes in Asian Indians. Anjana RM, Siddiqui MK, Jebarani S, Vignesh MA, Kamal Raj N, Unnikrishnan R, Pradeepa R, Panikar VK, Kesavadev J, Saboo B, Gupta S. Diabetes technology & therapeutics. 2022 Jan 5.
  22. A new interventional home care model for COVID management: Virtual Covid IP. Kesavadev J, Basanth A, Krishnan G, Vitale R, Parameswaran H, Shijin S, Sreelakshmi R, Raj S, Ashik A, Shankar A, Badarudeen S. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Jul 2021:102228.
  23. Steroid use during COVID-19 infection and hyperglycemia–What a physician should know. Sosale A, Sosale B, Kesavadev J, Chawla M, Reddy S, Saboo B, Misra A. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Jun 2021.
  24. Management Strategies for Dealing With Surges of the COVID-19 Pandemic. Raveendran A, Kesavadev J, Hari P, Krishnan G. Cureus 13(6). June 2021.
  25. Reply to the letter of Draves et al. In response to the article: "Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization" (Kesavadev et al.)". Kesavadev J, Misra A, Saboo B, Aravind SR, Hussain A, Czupryniak L, Raz I. Diabetes Metab Syndr. 2021 Jan-Feb;15(1):466. doi: 10.1016/j.dsx.2021.02.006. Epub 2021 Feb 7. PMID: 33589363.
  26. DIY artificial pancreas: A narrative of the first patient and the physicians’ experiences from India. Kesavadev J, Saboo B, Kar P, Sethi J. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. March- April 2021;15(2): 615-620;
  27. Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Kesavadev J, Misra A, Saboo B, Aravind SR, Hussain A, Czupryniak L, Raz I. January–February 2021: 221-227.
  28. Time-in-range as a target in type 2 diabetes: An urgent need.Saboo B, Kesavadev J, Shankar. A, Krishna M.B, Sheth S, Patel V, Krishnan G. Heliyon. Vol 7(3). Jan 2021: e05967.
  29. Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market. Murthy S, Aneja P, Asirvatham A.J, Husemoen L.L, Rhee N.A, Kesavadev J. Pharmaco Economics-Open, Jan 2021:1-3.
  30. The SAGE Study: Global Observational Analysis Of Glycaemic Control, Hypoglycaemia And Diabetes Management In T1DM. Renard E, Ikegami H, Daher Vianna AG, Pozzilli P, Brette S, Bosnyak Z, Lauand F, Peters A, Pilorget V, Jurišić-Eržen D, Kesavadev J, Seufert J, Wilmot EG. Diabetes/Metabolism Research and Reviews. 2020 Dec 28.
  31. Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel. Chawla M, Jain SM, Kesavadev J, Makkar BM, Viswanathan V, Tiwaskar M, Sosale AR, Negalur V, Modi KD, Gupta M, Kumar S, Ramakrishnan S, Deka N, Roy N. Diabetes Ther. 2020 Dec 12:1–10. doi: 10.1007/s13300-020-00979-8.
  32. Management of children and adolescents having type 1 diabetes during COVID-19 pandemic in India: challenges and solutions. Jethwani P, Saboo B, Jethwani L, Kesavadev J, Kalra S, Sahay R, Agarwal S, Hasnani D. International Journal of Diabetes in Developing Countries. 2020 Sep;40(3):335-9.
  33. A 2020 Update On Diabetes Technologies With Emphasis On Telemedicine During COVID-19. Kesavadev J. Kerala Medical Journal. Vol 12: issue 3;Jul- sept 2020: 112-115.
  34. Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas. Kesavadev, J., Saboo, B., Krishna, M.B. et al. Diabetes Ther. 2020;10.1007/s13300-020-00831-z.
  35. Harnessing the Possibilities of Telemedicine for Consultations in COVID Crisis. Kesavadev J. Int J Diab 2020;1-6
  36. The Do-It-Yourself Artificial Pancreas: A Comprehensive Review. Kesavadev J, Srinivasan S, Saboo et al. Diabetes Ther (2020). https://doi.org/10.1007/s13300-020-00823-z
  37. Real-world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register. Kong APS, Lew T, Lau ESH, Lim LL, Kesavadev J. et al. Diabetes Obes Metab. 2020 Apr;22(4):669-679.
  38. Inertia for the Use of Technological Advances for Effective Diabetes Management. Kesavadev J. Int J Diab 2019.1-2. Editorial.
  39. Exploratory CSII Randomized Controlled Trial on Erectile Dysfunction in T2DM Patients (ECSIITED). Kesavadev J, Sadasivan PP, Shankar A, Warrier RS, Ramachandran L, Jothydev S, Krishnan G. J Diabetes Sci Technol. 2018. 12(6). 1252–1253.
  40. Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program. Gani L, Lau E, Luk A, Sobrepena L, Tran QK, Kesavadev J, Jia W, Yu W, Tsang CC, Mukhopadhyay M, Jha S, et al. J Diabetes Investig. 2018. 9(6). 1312–1322.
  41. Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges. Kesavadev J, Shankar A, Ashok AD, Srinivas S, Ajai NA, Sanal G, Krishnan G, Ramachandran L, Jothydev S. J Diabetes Sci Technol. 2018. 12(1). 230–231.
  42. Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation. Kesavadev J, Vigersky R, Shin J, Pillai PBS, Shankar A, Sanal G, Krishnan G, Jothydev S. Adv Ther. 2017. 34(8). 1918-1927.
  43. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes. Kesavadev J, Pillai PB, Shankar A, Krishnan G, Jothydev S. Endocrine Connections. 2017 Nov 1;6(8):748-57.
  44. Glucose monitoring technologies - complementary or competitive? Role of continuous glucose monitoring versus flash glucose monitoring versus self-monitoring of blood glucose. Kesavadev J, Ramachandran L, Krishnan G. Journal of Diabetology. 2017;8(3):61-93.
  45. Efficacy and safety concerns regarding Complementary and Alternative Medicine use among diabetes patients. Kesavadev J. The Journal of the Pakistan Medical Association. 2017;67(2):316.
  46. Consensus recommendations on exploring effective solutions for the rising cost of diabetes. Sadikot SM, Das AK, Wilding J, Siyan A, Zargar AH, Saboo B, Aravind SR, Sosale B, Kalra S, Vijayakumar G, Manojan KK, Maheshwari A, Panda JK, Banerjee S, Chawla R, Vasudevan SP, Sundar OSS, Kesavadev J. Diabetes Metab Syndr. 2017. 11(2). 141-147.
  47. A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes. Anjana RM, Kesavadev J, Neeta D, Tiwaskar M, Pradeepa R, Jebarani S, Thangamani S, Sastry NG, Brijendra Kumar S, Ramu M, Gupta PPK, Vignesh J, Chandru S, Kayalvizhi S, Jagdish PS, Uthra SCB, Lovelena M, Jyoti S, Suguna Priya S, Kannan A, Mohan V, Unnikrishnan R. Diabetes Technology & Therapeutics. 2017;19(9):533-4.
  48. Platelet Proteins from Diabetic Subjects Cause Phenotypic Changes in Endothelial Cells In-Vitro. Hilary S, Shahna S, Kesavadev J, Bhatt A. International Journal of Life Science And Pharma Research. 2017;7(1):61-71.
  49. From Insulin Pumps to Artificial Pancreas: Indian Experience over 12 years. Kesavadev J, Krishnan G. Kerala Medical Journal. 2016;9(3):6.
  50. Unproven Therapies for Diabetes and Their Implications. Kesavadev J, Saboo B, Sadikot S, Das AK, Joshi S, Chawla R, Thacker H, Shankar A, Ramachandran L, Kalra S. Adv Ther. 2016:1-18.
  51. Insulin pump therapy in pregnancy. Kesavadev J. J Pak Med Assoc. 2016 Sep;66(9 Suppl 1): S39-44.
  52. Use of Retrospective Continuous Glucose Monitoring for Optimizing Management of Type 2 Diabetes in India. Mohan V, Jain S, Kesavadev J, Chawla M, Mutha A, Viswanathan V, Saboo B, Kovil R, Mithal A, Punatar D, Shin J. J Assoc Physicians India. 2016 Apr;64(4):16-21.
  53. The two levels of care for diabetes in a developing country: Mechanisms for improved intermediate health outcomes. Vitale RJ, Pillai PB, Krishnan G, Jothydev S, Kesavadev J. Diabetes Metab Syndr. 2016 Jan-Mar;10(1 Suppl 1): S90-4.
  54. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. LEADER Trial Investigators. N Engl J Med. 2016 Jul 28;375(4):311-22.
  55. CSII as an Alternative Therapeutic Strategy for Managing Type 2 diabetes: Adding the Indian Experience to a Global Perspective. Kesavadev J, Shankar A, Pillai PB, Saboo B, Joshi S, Krishnan G, Jothydev S. Curr Diabetes Rev. 2016 ;12(4):312-314.
  56. Consensus Statement on Management of Post-Prandial Hyperglycemia in Clinical Practice in India. Aravind S, Saboo B, Sadikot S, Shah SN, Makkar B, Kalra S, Kannampilly J, Kesavadev J, Ghoshal S, Zargar A, Nigam A, Hazra D, Tripathi K, Dharmalingam M, Shah P, Gandhi P, Sahay R, Unnikrishnan R, Gupta S, Bajaj S, Mukhopadhyay S, Kale S. J Assoc Physicians India. 2015 Aug;63(8):45-58.
  57. Telemedicine for diabetes care: An Indian perspective - feasibility and efficacy. Kesavadev J, Saboo B, Shankar A, Krishnan G, Jothydev S. Indian J Endocrinol Metab. 2015 Nov-Dec;19(6):764-9.
  58. Intensifying Insulin Therapy in Type 2 Diabetes: Choices & Challenges. Kumar A, Kesavadev J, Sethi B, Jain SM, Guruprasad CS, Shah SN. J Assoc Physicians India. 2015 May;63(5 Suppl):8-14.
  59. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42.
  60. Fasting in Ramadan with an insulin pump. Kesavadev J. J Pak Med Assoc. 2015 May;65(5 Suppl 1):S47-50.
  61. Consensus evidence-based guidelines for use of insulin pump therapy in the management of diabetes as per Indian clinical practice. Kesavadev J, Jain SM, Muruganathan A, Das AK; Diabetes Consensus Group. J Assoc Physicians India. 2014 Jul;62(7 Suppl):34-41.
  62. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Diabetes Metab Syndr. 2015 Jan-Mar;9(1):30-3.
  63. Understanding the safety of the new ultra long acting basal insulin. Ramachandran A, Gupta V, Kesavadev J, Kalra S. J Assoc Physicians India. 2014 Jan;62(1 Suppl):35-42.
  64. Challenges in Type 1 diabetes management in South East Asia: Descriptive situational assessment. Kesavadev J, Sadikot SM, Saboo B, Shrestha D, Jawad F, Azad K, Wijesuriya MA, Latt TS, Kalra S. Indian J Endocrinol Metab. 2014 Sep;18(5):600-7.
  65. Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. Kesavadev J, Sadikot S, Wangnoo S, Kannampilly J, Saboo B, Aravind SR, Kalra S, Makkar BM, Maji D, Saikia M, Anjana RM, Rajput R, Singh SK, Shah S, Dhruv U, Vishwanathan V. Diabetes Metab Syndr. 2014 Jul-Sep;8(3):187-95.
  66. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study. Kesavadev J, Joshi SR. J Assoc Physicians India. 2013 Jan;61(1 Suppl):28-30.
  67. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve study. Kesavadev J. Indian J Endocrinol Metab. 2013 Nov;17(Suppl 2):S565-8.
  68. Barriers and solutions to diabetes management: An Indian perspective. Wangnoo SK, Maji D, Das AK, Rao PV, Moses A, Sethi B, Unnikrishnan AG, Kalra S, Balaji V, Bantwal G, Kesavadev J, Jain SM, Dharmalingam M. Indian J Endocrinol Metab. 2013 Jul;17(4):594-601.
  69. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Diabetes Obes Metab. 2013 Aug;15(8):729-36.
  70. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus--a retrospective study. Kesavadev J, Shankar A, Pillai PB, Krishnan G, Jothydev S. Diabetes Technol Ther. 2012 Sep;14(9):772-6.
  71. Suggested use of vaccines in diabetes. Kesavadev J, Misra A, Das AK, Saboo B, Basu D, Thomas N, Joshi SR, Unnikrishnan AG, Shankar A, Krishnan G, Unnikrishnan R, Mohan V. Indian J Endocrinol Metab. 2012 Nov;16(6):886-93.
  72. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Int J Gen Med. 2012;5:317-22.
  73. Continuous insulin infusion systems in type 2 diabetes. Kesavadev J. J Assoc Physicians India. 2011 Apr;59 Suppl:41-3.
  74. An Asian Indian woman with Wolfram syndrome on insulin pump: successful pregnancy and beyond. Kesavadev J, Kumar A, Shankar A, Gopalakrishnan G, Permutt MA, Wasson J, Jothydev S. Diabetes Technol Ther. 2011 Jul;13(7):781-5.
  75. Use of insulin pumps in India: suggested guidelines based on experience and cultural differences. Kesavadev J, Das AK, Unnikrishnan R, Joshi SR, Ramachandran A, Shamsudeen J, Krishnan G, Jothydev S, Mohan V. Diabetes Technol Ther. 2010 Oct;12(10):823-31.
  76. Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes. Kesavadev J, Balakrishnan S, Ahammed S, Jothydev S. Diabetes Technol Ther. 2009 Aug;11(8):517-21.
  77. Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride. Kesavadev J, Rasheed SA. J Assoc Physicians India. 2006 Dec;54:951-2.
  78. Diabetes in old age: an emerging epidemic. Kesavadev JD, Short KR, Nair KS. J Assoc Physicians India. 2003 Nov;51:1083-94.

Selected Chapters in Textbooks:

  • Newer insulins on the horizon. Kesavadev J, Ramachandran L. RSSDI’s INSULIN Monograph (A Complete Guide to Insulin Therapy). Jaypee Brothers Medical Publishers (P) Ltd. 2020. 138-143.
  • Pathophysiology of Type 2 Diabetes. Kesavadev J, Jawad F, Deeb A, Coetzee A, Jalil Ansari M. A, Shrestha D, Somasundaram N, Kalra S. The Diabetes Textbook. 2019. 101-116.
  • Unproven Therapies for Diabetes. Kesavadev J, Ramachandran L, Kalra, S. The Diabetes Textbook. 2019. 999-1013.
  • Kesavadev J. Brittle Diabetes: Challenges to the Physicians. Chapter 30, Section 12. SMART Medicine update -2017. Jaypee Brothers Medical Publishers 2017.
  • Kesavadev J. Insulin Pump Therapy: How to Choose the Right Candidate. Chapter 8. RSSDI Diabetes Update 2016.
  • Kesavadev J. In Hospital Management of Diabetes mellitus. API Progress in Medicine 2017.
  • Kesavadev J. Evolution of Path-breaking Technologies in Diabetes. Chapter 21. Volume 2. API Progress in Medicine 2016.
  • Kesavadev J. The Bittersweet Aroma of Inhaled Insulin. Chapter 18. RSSDI Annual Conference Update 2015.
  • Kesavadev J. Use of Insulin Pump in Type 1 Diabetes Mellitus. Chapter 18. Clinical Case Series in Diabetes. Jaypee Brothers Medical Publishers 2015.
  • Kesavadev J. Will the Technological Advances in Devices have Place in Diabetes Management in India? Micro labs Ltd. 2015.
  • Kesavadev J. Clinical Benefits of Liraglutide: Taking Therapy into the Real World. API Medicine Update Vol. 24: 2014.
  • Kesavadev J. Insulin pumps in Type 1 diabetes. RSSDI Annual Conference Update 2014.
  • Kesavadev J. Immunization in Diabetes. Diabetes Suraksha. Macmillan Medical Publishers 2014
  • Kesavadev J. Continuous Glucose Monitoring System, Chapter 41, RSSDI Textbook of Diabetes 2013.
  • Kesavadev J. Various Emerging Techniques in Insulin Delivery Systems. Innovative Approaches in Type 2 diabetes. Chapter 42. Page 398-408. Micro labs Ltd.
  • Kesavadev J. Very Low Protein Diet with Ketoanalogue Supplementation in Diabetic Kidney Disease: Case Studies. Dietary Protein Restriction in Chronic Kidney Disease. Page 35-44 Published by Elsevier India Pvt.Ld.
  • Kesavadev J. Insulin Pump in Type 2 diabetes mellitus. Jaypee Brothers Medical Publishers (P) Ltd.Page 120-133 World Clinics Diabetology Type 2 diabetes mellitus.World Clin Diabetol.2014;1(1):120-33.
  • Kesavadev J. Insulins in Continuous Subcutaneous Insulin Infusion”, Asian Journal of Diabetology, April-June 2010.
  • Kesavadev J. Newer Insulin and Insulin pumps", The Journal of the Association of Physicians of India (Tamil Nadu Chapter) (TAPIJ), May-Aug 2010.

Selected Presentations:

  • Advanced Technologies & Treatments for Diabetes, 16th International Conference, Berlin and Online, February 22–25, 2023
    • Do-it-yourself Artificial Pancreas: The Affordable Indian Experience. Kesavadev J. (Invited Speaker)
    • Assessing TIR Metrics and A1C in PwD and its Association with Treatment Related Variables. Kesavadev J, Shankar A, Krishnan G, Saboo B, Joshi S, Chawla M, Basanth A, Jothydev S.
    • Effects of Customised Structured SMBG on Glycemic Control in People with Diabetes over 10 Years. Kesavadev J, Shankar A, Jothydev K, Krishnan G, B. Saboo, Joshi S, Sanal G, Rajalekshmi S, Basanth A, Jothydev S.
  • International Diabetes Federation (IDF) Congress, Lisbon, December 5-8, 2022
    • Points in Range (PIR) as an alternative to Time in Range in Resource-Limited Settings. Kesavadev J, Saboo B, Joshi R. S, Shankar A, Krishnan G, Sanal G, Lally J, Basanth A, Jothydev S.
    • User Perception and Satisfaction with an Advanced Hybrid Closed Loop System: The Experience from Kerala. Krishnan G, Kesavadev J, Shankar A, Unes Y, Ashik A, Sanal G, Krishna V, Rajalakshmi S, Basanth A, Jothydev S.
    • A Reliable risk score for ASCVD in Indian type 2 diabetes. Ashik A, Johnson J, Kesavadev J, Shankar A, Krishnan G, Basanth A, Jothydev S.
    • Merits and Demerits of using Telemedicine based program for Diabetes Management. Kesavadev J, Saboo B, Jothydev K, Shankar A, Krishnan G, Lally J, Sanal G, Rajalakshmi S, Jothydev S.
    • Fibroscan as an easy-to-use tool in predicting NAFLD progression in diabetes. Shankar A, Kesavadev J, Krishnan G, Jose R, Basanth A, Jothydev S.
  • International Society for Pediatric and Adolescent Diabetes, 48th Annual Conference, United Arab Emirates, October 13-16, 2022
    • Comparing points in target range assessed by Blood Glucose Monitoring (BGM) using a vacuum-based lancing device and a conventional lancing device. Kesavadev. J, Beena Chandran G, Krishnan G, Basanth A, Shankar A, Jothydev S.
  • Advanced Technologies & Treatments for Diabetes, 15th International Conference, Barcelona, April 27-30, 2022
    • Can Physical Activity as an Independent Parameter Influence TIR?. Kesavadev J, Shankar A, Krishnan G, Sanal G, Basanth A.
    • Comparing the Benefits of a Painless Lancing Device in People with Diabetes in Improving Self-Monitoring Frequency and HbA1c. Kesavadev J, Beena Chandran G, Basanth A, Krishnan G, Shankar A.
    • WhatsApp support group for 950 children and adolescents/parents with type 1 diabetes - Physician’s perspective on merits and demerits. Kesavadev J. (Invited Speaker)
  • International Society for Pediatric and Adolescent Diabetes, 47th Annual Conference, Virtual, October 13-15, 2021
    • Role of a multidisciplinary team assisted, technology-enabled education program in empowering people with type 1 diabetes (e-poster presentation). Kesavadev J, Saboo B, Shijin S, Shankar A, Unes Y, Sanal G, Krishna V, Basanth A, R S, Beena Chandran G, Krishnan G, Jothydev S.
  • American Diabetes Association, 81st Scientific Sessions, Virtual, June 25-29, 2021
    • Comparing Telemedicine with Conventional Diabetes Care in Assessing Long-Term Outcomes in 451 Patients over 15 Years. Kesavadev J, Shankar A, Krishnan G, Ajith J, Basanth A, Jothydev K, Chandran B, S. S, Jothydev S. ADA, 81ST Scientific Sessions, Virtual, June 25-29, 2021. 853-P
    • Impact of Webinars and Telemedicine during COVID-19 Lockdown in Transforming Outcomes in 848 T2D Patients in India. Kesavadev J, Shankar A, Krishnan G, Basanth A, Jothydev K, Chandran B, S. S, Jothydev S. ADA, 81ST Scientific Sessions, Virtual, June 25-29, 2021. 468-P
  • Advanced Technologies & Treatments for Diabetes, 14th International Conference, Virtual, June 2-5, 2021
    • Using Telemedicine and remote monitoring for diabetes during COVID-19: The Indian experience. (Invited Lecture)
    • Virtual Covid IP Care In Diabetes: Concept to Reality. (Oral Presentation). Kesavadev. J, Shankar. A, Unes. Y, Shijin. S, Manoj. A, Rajalakshmi S, Jose. R, Krishnan G, Jothydev. S.
    • Can An Advanced Lancing Device Alleviate Pain And Improve HbA1c? Kesavadev J, Shankar. A, Krishnan G, Chandran B, Basanth A, Sanal G, Krishna V, Jothydev S.
    • Rediscovering The Power Of Telemedicine (DTMS®) In The Covid Era. Kesavadev J, Saboo B, Shankar A, Krishnan G, Ashok A, Ajith J, Manoj A, S. S, Basanth A, Jyogesh S, Jothydev S.
  • Advanced Technologies & Treatments for Diabetes, 13th International Conference, Madrid, Spain, Feb 19-22, 2020
    • Utility of a Glucose meter with Bluetooth and Web Connectivity in Aiding Physicians and Patients Achieve Better Glycemic Levels. Kesavadev J,Krishnan G , Shankar A , Ashok A, Shamsudeen J ,Thampiraj K ,Manu A ,Jothydev S. Diabetes Technol Ther. 2020 Feb. 22(S1). A109.
    • Outlining the Relationship Between Time In Target (TIT) and HbA1c in Asian Indians with Diabetes. Kesavadev J, Shankar A, Warrier R, Krishnan G, Shamsudeen J, Jothydev S. Diabetes Technol Ther. 2020 Feb. 22(S1). A131.
  • American Diabetes Association, 79th Scientific Sessions, San Francisco, CA. June 7-11, 2019
    • Early insulin initiation in T2DM is associated with prevention of eGFR decline and lower insulin dose requirements. Kesavadev J, Warrier R, Shankar A, David A, Ajai N. A, Sanal G, Thampiraj K, Ramachandran L, Krishnan G, Jothydev S.
    • Improving the Quality of Life of T1DM Patients in a Community: A KT1DP Initiative. Kesavadev J, Saboo B. D, Shankar A, David A, Warrier R, Ajai N. A, Sanal G, Thampiraj K, Ramachandran L, Krishnan G, Jothydev S. Diabetes Jun 2019, 68 (Supplement 1)
    • Consistency and Predictability of Control of Glycemic Variability with U200 (Concentrated r-DNA Human Insulin Premix 30/70-200 IU/mL) in Type 2 Diabetes Mellitus Patients. Thacker H, Kesavadev J, Ingole S. A, Shah A, Jain R. Diabetes Jun 2019, 68 (Supplement 1)
  • Advanced Technologies & Treatments for Diabetes, 12th International Conference, Berlin, Germany, Feb 20-23, 2019
    • Harnessing the Power of Social Media for a Structured and Instant Intervention, Education and Counselling in Type 1 Diabetes. Kesavadev J,Shankar A, David A, Sanal G, Ajith J, Krishnan G, Ramachandran L, Jothydev S. Diabetes Technol Ther. 2019 Feb. 21. A116.
    • Assessing the Benefits of a Painless Lancing Device in a Subset of Patients Fearful of Finger Pricking. Warrier R, Badarudeen S, Shankar A,Krishnan G, Ramachandran L, Thampiraj K, Jothydev S, Kesavadev J. Diabetes Technol Ther. 2019 Feb. 21. A60-A61.
  • American Diabetes Association, 78th Scientific Sessions, Orlando, Florida, 2018
    • IDegAsp Improves Glycemic Control with Minimal Hypoglycemia—An Indian Real-World Study in T2D Subjects. Jothydev Kesavadev, Banshi D. Saboo, Arun Shankar, Ashwin David,Rohit Warrier, Gopika Krishnan, Lakshmy Ramachandran, Sunitha Jothydev. Diabetes Jul 2018, 67 (Supplement 1) 389-P; DOI: 10.2337/db18-389-P.
    • Are Complications Preventable with Periodic Education via Telemedicine? A Study of 414 Compliant T2D Patients Followed Up for 19 Years. Jothydev Kesavadev, Arun Shankar, Ashwin David, Gopika Krishnan, Neethu A. Ajai, Geethu Sanal, Jaysree Ajith, Soumya Jayanthi, Lakshmy Ramachandran, Sunitha Jothydev. Diabetes Jul 2018, 67 (Supplement 1) 685-P; DOI: 10.2337/db18-685-P.
    • Enabling Data-Driven Decision Making for Personalized Care in Type 2 Diabetes with Clinical and Lifestyle Journey Data Using a Digital Therapeutic. Rajeev Chawla, Maaz Shaikh, Abhishek Shah, Banshi D. Saboo, Brij M. Makkar, Jothydev Kesavadev, Shilpa Joshi, Neeta Deshpande, Sanjay Agarwal, Anuj Maheshwari, Aravind R. Sosale, Sv Madhu. Diabetes Jul 2018, 67 (Supplement 1) 248-OR; DOI: 10.2337/db18-248-OR.
    • Efficacy of a Basal-Plus Regimen. Banshi D.J. Saboo, Dhruvi Hasnani, Hardik Chandarana, Sudhir Bhandari, Shashank Joshi, Jothydev Kesavadev, Anuj Maheshwari, Hemant Thacker. Diabetes Jul 2018, 67 (Supplement 1) 2292-PUB; DOI: 10.2337/db18-2292-PUB.
    • Conversational Artificial Intelligence for Achieving Activity Targets through Routine Physical Activity—Longitudinal Observational Study among People with Type 2 Diabetes. Brij M. Makkar, Maaz Shaikh, Abhishek Shah, Shilpa Joshi, Banshi D. Saboo, Aravind R. Sosale, Sv Madhu, Rajiv Kovil, Tejas Shah, Manoj S. Chawla, Rajeev Chhawla, Jothydev Kesavadev. Diabetes Jul 2018, 67 (Supplement 1) 750-P; DOI: 10.2337/db18-750-P.
    • One-Year Safety and Effectiveness of Insulin Degludec in Patients with Diabetes Mellitus in Routine Clinical Practice in India—TRUST (Tresiba Real-World Use Study). Jothydev Kesavadev, L. Sreenivasa Murthy, Banshi D. Saboo, Sadasiva Rao Yalamanchi, Balamurugan Ramanathan, Sunil Gupta, Sanjay Chatterjee, Manjunatha Revanna, Harsha Kasetty. Diabetes Jul 2018, 67 (Supplement 1) 1019-P; DOI: 10.2337/db18-1019-P.
    • Continuous Glucose Monitoring Guided Assessment of Concentrated U200 r-DNA Human Premix 30/70 Insulin. Hemant Thacker, Jothydev Kesavadev, Gursimran Singh, Kirti Shukla, Gaurav Puppalwar, Rupal Shrimanker. Diabetes Jul 2018, 67 (Supplement 1) 1013-P; DOI: 10.2337/db18-1013-P.
  • Invited speaker at 8th Emirates Diabetes and Endocrine Congress (EDEC 2018)
  • Advanced Technologies & Treatments for Diabetes International Conference, Austria, 2018
    • SMBG and virtual consultation via DTMS®: 20 years' experience (Invited Lecture). Patient and caregiver feedback on the first generation Artificial Pancreas in India. Diabetes duration-based initiation of insulin: impact on clinical outcomes, insulin dosage and quality of life.
    • Utility of a multi-model bot enabled, and doctor led intervention for diabetes management- clinician and patient perspectives.
  • International Diabetes Federation (IDF) Congress, Abu Dhabi, UAE, 2017
    • Insulin delivery methods- Past, present and future (Invited Lecture).
    • The impact of un-proven complementary and alternative medicine practices in diabetes management – an Indian scenario.
    • Free insulin pumps to type 1 diabetes children – KT1DP initiative.
    • Elderly living alone with diabetes – an emerging major social issue?
  • American Diabetes Association, 77th Scientific Sessions, San Diego, California, 2017
    • Halting CKD Progression in Diabetes with Virtual Interactions- a 5 year Retrospective Analysis.
    • The significance of repeated education in correcting insulin injection techniques and improving glycemic control.
  • Diabetes India 2017- Invited lecture
    • The limitation of HbA1c - Flash Glucose Monitoring: Clinical Use.
  • Diabetes India 2017- Invited lecture
    • Bionic Pancreas: The Dream Come True?
  • Advanced Technologies & Treatments for Diabetes 9th International Conference 2017, Paris
    • Better Outcomes In Type 2 Diabetes Management With A User Friendly Flash Glucose Monitoring System- Freestyle Libre Pro- Oral Presentation.
  • American Diabetes Association, New Orleans, 2016
    • How Successful Is Lifestyle Advice in Preventing the Progression of Prediabetes to Diabetes.
    • Comparison of the New Factory Calibrated Sensor with Existing CGM Sensor.
  • Advanced Technologies & Treatments for Diabetes 9th International Conference 2016
    • Periodic follow up with telemanagement system for 15 years and significant reduction in vascular complications in T2DM.
    • Comparing iPro2 with Libre for Sensor Accuracy and User Friendliness.
  • International Diabetes Federation World Diabetes Congress, Vancouver, Canada, 2015
    • How significant are wrong injection techniques in a real world diabetes care setting?
    • Cost effective customisation of targets: Outcomes after 12 years of telemedicine in 853 patients with type 2 diabetes.
    • How proactive is the spouse support in diabetes care?
    • Unity in diversity: Religious festivals and its impact on diabetes in India.
  • American Diabetes Association, Boston, 2015
    • Comparing two models of diabetes care: comprehensive education and telemonitoring vs. limited care.
    • Insulin-sparing effect of and Severe Hypoglycemia with Sitagliptin vs. Glimepiride.
    • Periodic CGM in T2DM: exploring benefits across various therapy choices.
    • Exploring and resolving the impact of food on post prandial glycemic excursions in a rice-eating population in S.India.
    • Utilization of Biosimilar insulin in Asian patients with diabetes – The Joint Asia Diabetes Evaluation (JADE) program.
  • Advanced Technologies & Treatments for Diabetes 8th International Conference, 2015
    • Impact of Insulin Pump Therapy on Erectile Dysfunction in Type 2 Diabetes.
    • Role of Home Blood Pressure Monitoring in Halting the Progression of Diabetic Kidney Disease: 6 Year Follow up Data
  • European Association for the Study of Diabetes (EASD), 2014
    • Prevalence of undetected thyroid disorders in subjects with diabetes in South India: a cohort analysis
  • American Diabetes Association, San Francisco, US, 2014
    • Continuous Glucose Monitoring in 432 T2D Patients for Assessment of Safety and Cost effectiveness in Reaching A1C Targets.
  • Advanced Technologies & Treatments for Diabetes 7th International Conference, 2014
    • Use of Insulin Pumps in T2D in India: merits and demerits learnt over a decade (Invited Speaker).
    • Clinical Utility of CGM in pre-diabetes and its impact on modifying lifestyles.
    • Live Brief Weekly Educational Questionnaire Via DTMS® as a tool to improve the acceptability and outcome in Type 2 Diabetes.
  • International Diabetes Federation World Diabetes Congress 2013
    • The young Indian female with type 1 diabetes: challenges with marriage- Oral presentation.
    • Continuous customised education via telemedicine: outcome data of events over 8 years.
    • Safety of pneumococcal and influenza vaccine in diabetes patients in South India.
    • High prevalence of Hypertension in Kerala population: Diabscreen Kerala.
  • European Association for the Study of Diabetes (EASD), 2013.
    • C-peptide levels not affected by duration of diabetes in a telemedicine based long-term follow up programme.
  • European Association for the Study of Diabetes (EASD), 2012.
    • Low requirements for average statins dosage in South Indian populations titrated to target lipid parameters.
  • Advanced Technologies and Treatment for Diabetes (ATTD), Paris, France, 2013
    • Attitudes and Behaviour Of Type 2 Diabetes Patients on Insulin Pumps.
    • Glycemic Variability in Type 2 Diabetes Correlates with Total Daily Dose of Insulin And Use of Sulfonlyureas.
  • Advanced Technologies and Treatment for Diabetes (ATTD), Barcelona, Spain, 2012
    • Acceptance of Continuous Glucose Monitoring (CGM) as a routine investigation in Diabetes.
    • Geographical Location And Effectiveness Of A Simple Telemedicine Program (DTMS®) In Diabetes.
  • American Diabetes Association, Chicago, Illinois 2013
    • Time of Insulin Initiation, Duration of disease and onset of Erectile Dysfunction in Indian men with T2D.
    • Long Term Impact of Initial Insulin Therapy in New Onset T2D: 5 year Retrospective Data.
    • Superiority of a Telemedicine Based Counselling in Ensuring Multi Drug Compliance in T2D.
    • Normal Vitamin D Levels Correlates with Lower HbA1c: A Cross Sectional Study Among 1270 Type 2 Diabetes Patients in South India.
  • American Diabetes Association, Philadelphia, Pennsylvania 2012
    • High Bed Time Glucose and Early Morning Low Sugars in Elderly Subjects with Type 2 Diabetes(T2DM): An Incidental Finding with Clinical Significance.
    • Patterns of Glycemic variability (GV) in Indian Type 2 diabetes (T2DM) patients on Insulin and Oral Hypoglycemic Agents (OHAs) and its Correlation with A1c and Hypoglycemia.
    • Efficacy and Safety of Liraglutide in 195 Patients with Type 2 Diabetes in India: A Retrospective Analysis.
  • International Diabetes Federation, World Diabetes Congress, Dubai, 2011
    • Tele-medicine via DTMS® is cost-effective and satisfactory: still why it fails in minority with T2DM?
    • Acceptability of a home delivered assessment of lab & vital signs in Diabetes mellitus & its role in treatment motivation- P-1798.
    • Effectiveness of Liraglutide in Routine Clinical Practice: Six Months Follow-Up Data from India- P-1852.
  • American Diabetes Association, San Diego, California, 2011
    • A1c, BP and LDL goals: Successful Use of Telemedicine (DTMS) in 1000 Compliant T2DM Subjects over 6 Months- 229-OR.
    • Utility of CGM over Conventional SMBG in Making Treatment Changes in Insulin Requiring T2DM Patients- 912-P.
    • Significance of Screening for Thyroid Disorders in Type 2 Diabetes- 1377-P.
    • Change in Antihypertensive Medication Dose Following Initiation of Liraglutide in Patients with Type 2 Diabetes Mellitus- 2357-PO.
  • Advanced Technologies and Treatment for Diabetes (ATTD), London, UK, 2011
    • CGM as a tool For Therapeutic Decision Making (TDM) In Type 2 Diabetes Mellitus- P-108.
    • Pregnancy, Wolfram Syndrome and Insulin Pump: benefits beyond glycemic control- P-109.
  • ESICON, 2010
    • Effectiveness and Tolerability of Once Daily Human GLP-1 Analogue Liraglutide in Patients with Type 2 Diabetes in A Real Life Clinical Practice Setting-PO
  • American Diabetes Association, Orlando, USA, 2010
    • Telefollow up and SMBG Via “DTMS”- A Cost Effective Tool for A1c Lowering – 2083-PO.
    • High Prevalence of Elevated Transaminases among T2DM in S.India – 2340-PO.
  • American Diabetes Association, New Orleans, USA, June 2009 (speaker)
    • Requirement of high dosage of insulin in previous users of Glibenclamide with uncontrolled diabetes – 2079-PO.
    • Role of CGM in modifying Diet and Lifestyles in Diabetes subjects – 268-OR.
  • American Diabetes Association, San Francisco, USA, June 2008
    • Experiences with Insulin Pump in 52 Patients with Type 2 Diabetes in India- 2021-PO.
    • Insulin Aspart Induced Lipoatrophy in a Patient on Insulin Pump- 2093- PO.
    • High Prevalence of Dyslipidemia and Hypertension Detected in a Screening Program for Diabetes in a Rural population of a Southern State in India, Kerala (DIABSCREEN KERALA-04) – 2424-PO.
    • A Study on the Effects of Acarbose in Reducing Post-Prandial Blood Glucose and Achieving HbA1c – 438-P.
  • American Diabetes Association, Chicago, June 2007
    • Achieving Desirable Glycemic Targets without the risks of Hypoglycemia using a Teletitration program -0421-P
    • Dramatic Response of Painful Peripheral Neuropathy with Insulin Pump in Type 2 Diabetes -2097-PO
  • World Diabetes Congress, International Diabetes Federation, Montreal, Canada 2009
    • Good Nutrition: Avoidance of excess weight with Pumps- Symposium (Invited Speaker).
    • Low compliance of Statins in Kerala Rural Population (Diabscreen 14).
    • Successful outcome of a multidisciplinary team over an individual approach in imparting diabetes education.
  • Advanced Technologies and Treatment for Diabetes, Basel, Switzerland, 2010
    • Significant Alleviation of Neuropathic Pain with Insulin Pumps (CSII) in T2DM subjects previously on MDI- Abstract [57]
  • Advanced Technologies and Treatment for Diabetes, Greece, 2009
    • Reasons for non compliance to Diabetes Tele Medicine Based Follow up Program in Type 2 Diabetes.
    • Insulin Pump in 56 Type 2 diabetes subjects: Improvement of sexual satisfaction and neuropathic symptoms.

Research Activities:

As Principal Investigator for several research studies, a few are given below –

  • Principal Investigator for Inhaled human insulin with the AERx iDMS as prandial monotherapy compared to combination therapy with metformin and glimepiride in type 2 diabetes: an 18 week, open-label, multicentre, randomized, parallel group trial with an 8-week extension to investigate efficacy and safety. (Protocol ID: NN1998-1787)
  • A 26 weeks randomized, multinational, open-labelled, two armed, parallel group, treat-to-target, once daily treatment trial with insulin detemir versus insulin glargine both in combination with metformin in subjects with type 2 diabetes.(NN304-1768)
  • Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy (TECOS)
  • A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen (NN1250-3585)(DEGLUDEC STUDY)
  • An extension trial to NN1250-3585 investigating safety and efficacy of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen. NN1250-3725
  • Use of telemedicine-based self-monitoring of blood glucose program to achieve target HbA1c value without serious symptomatic hypoglycaemia along with economic benefit in 1000 patients with type 2 diabetes mellitus. : Retrospective study (IIS)
  • A 24 week, open, multicentre, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents.LANTU_C_04589
  • A 24 –week, multi-center, double blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus CLAF237A23135
  • A long-term, multi-centre, international, randomized, double-blind, placebo-controlled trial to determine Liraglutide effects on cardiovascular events (LEADER : EX2211-3748)
  • A 20 week randomized, multinational, open labeled, 2-armed,parallel group comparison of twice daily subject driven titration of biphasic insulin aspart (BIAsp) 30 versus twice daily investigator-driven titration of biphasic insulin aspart (BIAsp) 30 both in combination with Metformin in subjects with type 2 diabetes inadequately controlled on basal insulin analogues
  • Effects of Continuous Subcutaneous Insulin Infusion (CSII) on Erectile Dysfunction in T2DM Patients: A Prospective, Exploratory, Controlled Trial. (IIS)
  • An open labelled, randomized, active-controlled, parallel-arm, single-center study on effect of sitagliptin on T2DM patients on treatment with metformin and insulin.(IIS)
  • The Indian Prevention of Diabetes Study – RSSDI
  • Evaluation of the efficacy and tolerability of bromocriptine in the treatment of uncontrolled type 2 diabetes mellitus (USV/BROMO/001)
  • PERSISTence on glimepiride-metformin fixed combination in everyday practice in Asia type 2 diabetes patients
  • Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL).
  • Assessing the benefits of a painless lancing device among diabetes subjects in improving self-monitoring frequency and HbA1c -Genteel SMBG (JDC/Y-19-06-22) – Genteel.
  • A prospective multi-centric, open label, single-arm, phase-4 study to evaluate the safety and efficacy of the canagliflozin + metformin hydrochloride IR fixed dose combination as an adjunct to diet and exercise to improve glycemic control in Indian adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate (28431754DIA4032).
  • Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes (NN9924-4437).
  • Efficacy and safety of once weekly insulin icodec compared to once-daily insulin degludec 100 units/mL, both in combination with insulin aspart, in adults with type 1 diabetes (ONWARDS 6).

Academic Activities:

  • Accredited Centre for RSSDI Fellowship Course in Diabetology
  • Course Director RSSDI Fellowship Course in Diabetology
  • Course Director JDC Diabetes Educator Course
  • Course Director National Diabetes Educator Program